与17-interleukin抑制剂相关的候群病风险:影响和管理
Hazrat Bilal1, Muhammad Nadeem Khan2, Sabir Khan1
1Department of Dermatology, Second Affiliated Hospital of Shantou University Medical College, Shantou, China.
Mycology
|April 1, 2024
概括
干白素-17 (IL-17) 抑制剂通过影响免疫反应来增加候选症的风险. 布罗达卢马布和比米齐祖马布的风险较高,需要对患者进行仔细的评估和对真菌感染的监测.
科学领域:
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 介质素-17 (IL-17) 途径对于粘膜免疫对抗菌病原体,如Candida,至关重要.
- IL-17抑制剂用于治疗炎症,但可以破坏这种保护机制.
研究的目的:
- 评估IL-17抑制剂与 кандидоз风险之间的关联.
- 为了比较不同IL-17抑制剂的 кандидоз风险.
主要方法:
- 对观察数据和临床试验结果的分析.
- 在接受secukinumab,ixekizumab, brodalumab和bimekizumab治疗的患者中查看候群病发率.
主要成果:
- IL-17 抑制剂与 кандидоз的发病率增加有关.
- 与secukinumab相比,布罗达卢马布和比米基祖马布的候选症风险更高;与ixekizumab的数据是不确定的.
- 更高的剂量和更长的治疗持续时间与增加的 кандидоз风险相关.
结论:
- 在处方IL-17抑制剂之前,医疗保健提供者必须评估患者的风险因素.
- 对于早期检测而言,对候群病症状的患者教育至关重要.
- 需要进一步的研究来确定特定的风险因素和评估预防策略.
相关概念视频
T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
Factors Affecting the Risk of Infection
11.8K
The hosts' susceptibility to infection depends on several factors. The integrity of the skin and mucous membranes helps protect the body against microbial attacks. When the skin is altered, the chance of infection, limb loss, and even death increases.
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
11.8K
Pulmonary Tuberculosis I
242
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
242
Immunodeficiency Diseases
937
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
There are three main causes of immunodeficiency...
937
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137


